Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
The original £24m came from July/August 2021. We didn't hear about MW mobile services until late 2021
So, it is possible that the £24m related to existing operations as at July/August (ie, STC, labskin, MW). However, the brokers know a lot about what is going on in the background, more than us that is for sure, so perhaps this was a factor. STC medical is also a new revenue stream
We shall await the DVRG forecast and see what GB provides us at that time
All time low. Surely £15m is ridiculously cheap for what MODE has to offer. The BTC trading platform with FCA regulation alone must be worth more.
Clearly sentiment here is rock bottom and the company only have themselves to blame. As a shareholder it is very much a case of bottom drawer time. Hopefully 2022 sees a return to the 40's and above. Very disappointing first 15 months on the market for MODE
I think the company's main focus has been building the merchant arm of the business. This has not worked well so far. The boots/homebase/ocado debacle has crashed the SP to current levels.
The best decision they could make now is to focus on adding new crypto currencies. Build up a core following and build the SP with us focusing on replicating the big boys and let the merchant arm tick over in the background.
The MODE SP was around 50-60p before we even knew of the merchant offering plans. The merchant side show has very much killed the SP following the early optimism, imo
And good find Ragnar!
@GB, sounds like we have competition in Italy when this "tool" is ready in 2 or 3 months.
Unless...
There has quite clearly been an over reaction to the RNS, and in the wrong direction. The news regarding STC medical, and progress elsewhere, was very positive. Orders exceeded £10m but due to staff shortages, due to covid, DVRG could not deliver those orders when expected (very understandable). So, eventual turnover came in £670k under the target. Really nothing major under the circumstances and the orders had been received.
That £670k missed turnover wiped about £5m off the MCAP. That is a multiple of 7x to turnover.
If this is how the market correlate turnover to MCAP does that mean if DVRG deliver £24m in 2022 that the MCAP will be £168m? Answer: Unlikely. And thus over reaction to the RNS. Imo
£9.33m is slightly less than the targeted £10m, but the reasons for this (covid absences of staff) are understandable. It looks like around £1m or so has been pushed back in 2022, which gives us an early head start.
I am satisfied with this RNS. We knew 2021 revenue had to be £9m-£11m. So either way there isnt anything unexpected from a revenue perspective.
No mention of 2022 forecast, but hopefully we get more info on that in the next week.
STC medical looks interesting. What we dont know is whether the medical practitioners will be employed by DVRG or whether DVRG will refer users to external dermatologists for a commission. Either way, it opens up a avenue for those users who have skin conditions and want something doing about it. DVRG can clearly detect the issues they just can't provide the medical assistance... until now
Good posts all. I agree revenue guidance for 2022 must be in the region of £24m. I honestly cant imagine GB wanting to draw attention to the TP research note if he was about to release an RNS stating £13m or something like that.
He would be hung out to dry my some of the more critical posters here.
The TP research note is quite old now, so an RNS from the company locking in a forecast will have a much greater effect on the SP than a tweet from GB about a 5 month old research note, both of which wont have reach a wide audience
The 3 years annualised return of 56.97 vs benchmark of 7.16? Impressive sign of the investor return within DVRG vs the market as a whole
You might need to help me out Chesh... :-)
I completely agree Glebe. We gained a lot of new investors in Sept 2020 when the BT was announced at the general meeting, at a time when covid stocks were "going to the moon". The SP rose to about 70p at that time, before crashing back down to earth. It didnt get to 70p on the back of sentiment alone, it rose due to the deluge of investors piling in. Some of those paid 50/60/70p a share. Those investors will be very unhappy at the moment, if they still hold. I believe the term is "being spiked". It comes with experiece not to pile into a share that has risen sharply. Wealth is built over time, not over night
I expect us to return to the 50/60/70 price range this year with the amount of news in the pipeline at present. I think the confirmation of 2021 revenue and the forecast for 2022 will kick start the rise. On 11th Jan 2021 DVRG confirmed a revenue expectation of £10m. The SP was 36p (a non-spiked high).
If DVRG confirm £9-£11m unaudited turnover for 2021 (nailed on as no RNS to the contrary) and then forecast £24m (per TP research note) then i cant see 23p and £50m mcap. Then we have the CR conclusion, STC medical, STC plus, PD mobile van service, BT news and more.
Now is the time to be buying imo
Especially when £9-£11m came from non-PD income.
If DVRG guide the market £24m then the £13-£15m uplift should be very manageable from STC and PD sales.
If STC captures the imagination of the UK, US and China (eventually) the sales could be huge. They will also be difficult to predict. 60,000 x 12 x £97* = £69.84m (if people fancy dreaming)
*assumes £97 provides one test/skin swab. I can't recall whether £97 is two or more tests. If it is, then the revenue potential falls accordingly
... and then there is STC medical. All we know at the moment is that "it's big"
Shorteverything, where has the suggestion of £21m come from? Do you mean 2022 turnover? Per the TP research note it's £24m, but DVRG haven't released an RNS yet
JR owns a substantial chunk of this company so the slump in the SP hurts him too. Whether it is a material portion of his own personal wealth or not, it is still hurting him. That is a saving grace vs most crashing stocks where the BOD don't have any skin in the game and keep raising at an ever reducing SP.
Prior to "that" RNS back in Nov the SP was in the mid 30's/low 40's. The crash over the past month is due to poor sentiment arising from the merchant fiasco. And rightly so. However, bad sentiment doesnt equate to fair value. It is up to the BOD to pull something out of the bag and prove that the MCAP of £20m is beyond a joke. JR said, at £50/60m mcap, that MODE was heavily undervalued vs it's US peers, whether you consider the US big boys peers or not is another matter...
My take on this is the PD is specifically a waste water surveillance device. For the reasons GB has mentioned the PD cannot be used at the olympics.
His tweet relating to how DVRG are helping detect covid at the olympics leads me to believe that DVRG are able to detect covid in drinking water, but dont specifically need the PD to detect it (ie, the affirmers/optimers chip can be installed in other microtox devices).
I am not aware that fresh water becoming contaminated with covid is necessarily an issue, but if its there, microtox will detect it (just not through the use of the PD on this occasion).
So, i guess DVRG have been given clearance to detect if covid is in the water athletes drink (as well as other contaminants), but not if its in the waste they excrete.
All imo based on the info available, perhaps GB could clarify
Growth can take two forms, organic (self generated) or external (acquisition). The former is slower, the latter quicker but at a cost.
DVRG/SKIN revenue has grown from £278k to £10m (est) through a combination of the two.
The MWG turnover boost has been acquired via external growth, the remainder through organic growth.
Discrediting the rise in turnover due to a portion of it coming from external growth is misguided. DVRG wont forever discount any benefit from MWG purely because they purchased it as opposed to reinventing it from scratch. In the year following acquisition it is natural for critics to say "you haven't really achieved the MWG revenue because it was there already". It was there already, but was contributory to another business. Going forward it is DVRG revenue. No two ways about it. As far as arguing about growth statistics, the proof and benefits will be in the future growth, at least as far as i am concerned.
The revenue splits pre and post acquisition in 2020 could be argued until the cows come home. But 2021 revenue and beyond will contain full contribution from all DVRG divisions, including modern water.
If the 2022 revenue expectation is in the region of £24m will the critics say that the forecast isnt accurate as some of it comes from modern water?
I believe Modern Water have been used in numerous olympics in the past. I don't think the winter olympics being in China has necesarily changed anything in that respect. Obviously great news, although no mention of value (imaterial? Or sensitive to competitors?)
It would have been great if the PD was being used there too, but perhaps they can't be manufactured on the scale required at this moment in time
Hi volmer, this tweet was posted by GB earlier on today:
https://mobile.twitter.com/gjbrandon/status/1478713688781737992
No RNS yet, so nothing is known about what STC medical is, but it per an earlier GB tweet "it's big"
GB's tweet on STC looks promising. STC medical seems to be a response to the 58% of more serious skin conditions identified in the STC swabs processed to date. Presumably DVRG is looking to launch a dermatology/advisory arm that can diagnose eczema, acne, rosea and worse. If we can identify it then it makes sense to add that string to our bow imo, and more importantly monetise that capability.
DVRG will no doubt give us the low down soon via the appropriate RNS channels, but it looks like 2022 will be an exciting year for both existing and new revenue streams.
The most important thing at this stage is growing the brand awareness. 30k people know of STC across at least two continents. I am not sure why you would subscribe to STC if you weren't taking a test, whether for free or paid for.
Either way, a test gives DVRG data which is valuable. It may well be connected to the STC medical tweet that GB sent out the other day. STC medical may be how DVRG will monetise that data. In which case, even the free tests will generate revenue from the data that is then sold on. For anyone who pays for a test, it's money in, money out for DVRG.
We still haven't seen much from media monks, at least i haven't yet. Hopefully this will ramp up in the coming weeks.
All imo of course, but enough for me to top up this morning at 23.44 (bargain), especially with news from the various modern water avenues, 2021 results and 2022 expectations imminent :-)